Compare AXR & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXR | STIM |
|---|---|---|
| Founded | 1961 | 2003 |
| Country | United States | United States |
| Employees | 49 | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.8M | 140.6M |
| IPO Year | 2010 | 2018 |
| Metric | AXR | STIM |
|---|---|---|
| Price | $25.53 | $1.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $30.00 | $3.00 |
| AVG Volume (30 Days) | 12.6K | ★ 2.6M |
| Earning Date | 03-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.60 | 57.25 |
| EPS | ★ 1.68 | N/A |
| Revenue | $12,831,000.00 | ★ $52,776,000.00 |
| Revenue This Year | $10.12 | $11.10 |
| Revenue Next Year | N/A | $11.92 |
| P/E Ratio | $15.35 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $0.80 |
| 52 Week High | $29.01 | $4.84 |
| Indicator | AXR | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 44.32 |
| Support Level | $23.76 | $1.21 |
| Resistance Level | $28.68 | $1.75 |
| Average True Range (ATR) | 1.33 | 0.14 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 27.45 | 29.60 |
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.